Florida Academic Centers Research and Education, LLC

Coral Gables, Florida 33134

0 studies enrolling now · 18 studies all time

What they study most

Alopecia, Alopecia Areata, Areata Alopecia, Atopic Dermatitis, Dermatitis, Dermatitis, Atopic, Eczema, Genetic Diseases, Inborn, Hair Diseases, Hidradenitis Suppurativa, Hypersensitivity, Hypersensitivity, Immediate

Studies at this site

• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata — Recruiting now
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) — Running, not enrolling
• A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata — Completed
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. — Running, not enrolling
• An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis — Stopped early
• Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa — Running, not enrolling
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study of LY3471851 in Participants With Psoriasis — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) — Stopped early
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy — Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis — Completed
• Treatment of Moderate Hidradenitis Suppurativa — Status unconfirmed